TIMs make impact on infants

Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.

Related Videos
Related Content

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022

FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum

March 7th 2023

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

August 5th 2021

What’s New in Pediatric Dermatology With Elizabeth (Lisa) Swanson, MD

February 18th 2023

The Cutaneous Connection: Episode 7- Tips and Tricks for Treating Young Skin of Color Patients

September 17th 2020

Non-Invasive Test That May Help Predict Eczema in Babies

December 22nd 2022

Treatment of Plaque Psoriasis in Children

December 20th 2022
© 2023 MJH Life Sciences

All rights reserved.